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Long-Term Outcomes of the ADRENAL Trial
To the Editor: We recently reported the pri-
mary results of the Adjunctive Corticosteroid 
Treatment in Critically Ill Patients with Septic 
Shock (ADRENAL) trial, which tested the hypoth-
esis that hydrocortisone would result in lower 
mortality than placebo among patients with 
septic shock.1 Further analysis of the trial data 
has been conducted according to a previously 
published statistical analysis plan, which desig-
nated death 6 months after randomization as a 
secondary end point.2 These data are now avail-
able and are reported here.
Among patients for whom trial data were 
available, data on death at 90 days after random-
ization were obtained for 1832 of 1853 patients 
(98.9%) assigned to hydrocortisone and 1826 of 
1860 (98.2%) assigned to placebo. At 6 months, 
we obtained data on vital status (alive or dead) 
for 1812 patients (97.8%) and 1803 patients 
(96.9%), respectively.
At 6 months, among the patients for whom 
data on vital status were available, 571 of 1812 
(31.5%) assigned to hydrocortisone and 574 of 
1803 (31.8%) assigned to placebo had died (odds 
ratio, 0.99; 95% confidence interval, 0.86 to 
1.13; P = 0.83). The results were not altered by 
adjustment for stratification variables or addi-
tional covariates, as described in our original 
article1 (Table S1 in the Supplementary Appen-
dix, available with the full text of this letter at 
NEJM.org). There was no significant heteroge-
neity in the effect of the trial regimen on the 
risk of death at 6 months in the six prespecified 
subgroups (Fig. 1), nor were there geographic 
differences (Fig. S1 in the Supplementary Ap-
pendix). We conclude that in adult patients with 
septic shock, hydrocortisone did not affect mor-
tality at 6 months after randomization; these 
findings are in concert with the 90-day mortal-
ity results published earlier in the Journal.
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Oxybutynin for Hot Flashes Due to Androgen Deprivation  
in Men
To the Editor: Nonhormonal treatments used 
for menopausal hot flashes in women have gen-
erally been found to have limited efficacy against 
hot flashes induced by androgen deprivation for 
the treatment of prostate cancer in men. Gaba-
pentin and venlafaxine have been found to have 
limited efficacy.1 Megestrol acetate, although 
modestly effective,2 can have hormonal side ef-
fects; it has also been associated with decreases 
in levels of prostate-specific antigen (PSA) after 
Figure 1. Subgroup Analysis of Death at 180 Days.
The odds ratio of death at 180 days in the six prespecified subgroups is shown. The size of the square representing the odds ratio re-
flects the relative numbers in each subgroup, and horizontal bars represent 95% confidence intervals. P values are for heterogeneity of 
the effect of the trial regimen on the primary outcome in each subgroup. Scores on the Acute Physiology and Chronic Health Evaluation 
(APACHE) II are assessed on a scale from 0 to 71, with higher scores indicating a higher risk of death (a score of ≥25 has been used as  
a cutoff point to identify patients at a higher risk for death). Data on admission type were missing for 1 patient in the placebo group; on 
the catecholamine dose for 14 in the hydrocortisone group and for 15 in the placebo group; on the APACHE II score for 2 and 2, respec-
tively; and on the time from shock onset to randomization for 6 and 7, respectively.
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